Thermo Fisher Scientific Inc. $TMO Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,675 shares of the medical research company’s stock after buying an additional 4,938 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Thermo Fisher Scientific were worth $61,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. J. Stern & Co. LLP increased its position in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $3,072,744,000. Auto Owners Insurance Co lifted its holdings in shares of Thermo Fisher Scientific by 57,845.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company’s stock worth $1,406,844,000 after purchasing an additional 2,423,706 shares during the period. T. Rowe Price Investment Management Inc. increased its holdings in Thermo Fisher Scientific by 2,183.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company’s stock worth $770,000,000 after buying an additional 1,270,643 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in Thermo Fisher Scientific by 19.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company’s stock worth $4,462,550,000 after buying an additional 1,230,872 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on TMO shares. DZ Bank began coverage on shares of Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 price objective on the stock. Sanford C. Bernstein assumed coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price target on the stock. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 price target on the stock. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the company from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Finally, KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $602.14.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $532.17 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99. The firm has a market capitalization of $197.77 billion, a P/E ratio of 29.26, a price-to-earnings-growth ratio of 2.36 and a beta of 0.87. The stock’s fifty day moving average is $484.57 and its two-hundred day moving average is $514.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter in the previous year, the firm earned $5.15 EPS. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.